- Details
- Description
Packaging Size:
60 capsules
Strength:
40 mg
Composition:
Mobocertinib
Treatment:
Anti-Cancer / Oncology
Form:
Capsule
Brand:
Mobonib 40
Quantity Unit:
Capsules
Manufacturer:
Ziska Pharmaceuticals Limited
Mobonib 40 (Mobocertinib) is an oral targeted anti-cancer medicine containing mobocertinib, an EGFR tyrosine kinase inhibitor designed to target EGFR exon 20 insertion mutations. It is used for the treatment of certain adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have these specific EGFR mutations, particularly following progression during or after platinum-based chemotherapy. Mobonib 40 is available as 40 mg capsules, with a pack size of 60 capsules.
